glp 1 drugs and muscle loss GLP-1 & What They Do Nutritional deficiencies and muscle loss

GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2030

IntroductionGlucagon-like peptide-1 receptor agonists (GLP-1 RA) are novel agents with proven cardiovascular (CV) benefits

It details preclinical and clinical evidence linking GLP-1 receptor activation to cardiovascular, renal, hepatic, neural, and joint anti-inflammatory effects while outlining uncertainties and future research needs.

I'm pleased to share that npj Metabolic Health and Disease is joining Communications Medicine on a new collection looking at the Therapeutic Landscape of GLP1 agonists.

Autoimmune thyroid disease (AITD), including Hashimoto thyroiditis and Graves disease, represents the most prevalent organ-specific autoimmunity and a major cause of thyroid dysfunction worldwide

Recent research suggests that semaglutide, a medication primarily used for type 2 diabetes and weight management, may also help reduce alcohol consumption